Pulse Biosciences holder to sell 75,000 shares

A shareholder of Pulse Biosciences (PLSE) has filed a notice to sell 75,000 shares of common stock under Rule 144.

Rhea-AI Filing Summary

A shareholder of Pulse Biosciences (PLSE) has filed a notice to sell 75,000 shares of common stock under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value of $1,556,250 based on the filer’s stated price.

The securities were acquired on 02/09/2026 through a cash exercise of stock options from the issuer, with payment also made on that date. The form indicates no other sales of the issuer’s securities by this person in the past three months.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for Pulse Biosciences (PLSE) disclose?

The filing discloses a planned sale of 75,000 PLSE shares. A shareholder intends to sell common stock under Rule 144 via Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value reported as $1,556,250 at the time of the notice.

How many Pulse Biosciences (PLSE) shares are intended to be sold and on which exchange?

The notice covers 75,000 shares of PLSE common stock. These shares are listed for sale on the NASDAQ exchange, with the transaction to be executed through Morgan Stanley Smith Barney’s Executive Financial Services business.

How were the 75,000 Pulse Biosciences (PLSE) shares acquired?

The 75,000 PLSE shares were acquired through a stock option exercise. The filing states they were obtained on 02/09/2026 from the issuer via exercise of stock options, with the purchase price paid in cash on the same date.

What market value does the Form 144 assign to the Pulse Biosciences (PLSE) shares?

The filing reports an aggregate market value of $1,556,250. This value corresponds to the 75,000 common shares proposed for sale, based on the filer’s stated market price at the time of preparing the notice.

How many Pulse Biosciences (PLSE) shares are outstanding according to the filing?

The notice states that 67,767,578 PLSE shares are outstanding. This figure provides context for the planned 75,000-share sale, showing the proposed transaction size relative to the total common shares of the issuer.

Does the Pulse Biosciences (PLSE) Form 144 mention recent prior sales by the same holder?

The filing does not list any prior sales in the past three months. The section for securities sold during the previous three months contains no disclosed transactions for the person on whose behalf this notice is filed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/09/2026 - 04:30 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001913245
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	PULSE BIOSCIENCES INC
SEC File Number	001-37744
Address of Issuer	601 Brickell Key Drive, Suite 1080 Miami FLORIDA 33131
Phone	510-906-4600
Name of Person for Whose Account the Securities are To Be Sold	KEVIN DANAHY
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	75000	1556250.00	67767578	02/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/09/2026	Exercise of Stock Options	Issuer			75000	02/09/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
Date of Notice	02/09/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/14/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Kevin Danahy
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)